DK3507306T3 - Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer - Google Patents

Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer

Info

Publication number: DK3507306T3
Authority: DK; Denmark
Prior art keywords: stimulatory; binding; checkpoint receptors; immunomodulatory antibodies; bispecific immunomodulatory
Prior art date: 2016-08-30

Application number

DK17765002.5T

Other languages

English (en)

Inventor

Matthew Bernett

Gregory Moore

John Desjarlais

Michael Hedvat

Christine Bonzon

Umesh S Muchhal

Original Assignee

Xencor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-30

Filing date

2017-08-30

Publication date

2025-10-20

2017-06-14 Priority claimed from US15/623,314 external-priority patent/US10787518B2/en

2017-08-30 Application filed by Xencor Inc filed Critical Xencor Inc

2017-08-30 Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en

2025-10-20 Application granted granted Critical

2025-10-20 Publication of DK3507306T3 publication Critical patent/DK3507306T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

DK17765002.5T 2016-08-30 2017-08-30 Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer DK3507306T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662381239P	2016-08-30	2016-08-30
US201762456033P	2017-02-07	2017-02-07
US201762479723P	2017-03-31	2017-03-31
US15/623,314 US10787518B2 (en)	2016-06-14	2017-06-14	Bispecific checkpoint inhibitor antibodies
PCT/US2017/049497 WO2018045110A1 (en)	2016-08-30	2017-08-30	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Publications (1)

Publication Number	Publication Date
DK3507306T3 true DK3507306T3 (da)	2025-10-20

Family

ID=65632988

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17765002.5T DK3507306T3 (da)	2016-08-30	2017-08-30	Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer

Country Status (12)

Country	Link
EP (1)	EP3507306B1 (da)
JP (2)	JP7080219B2 (da)
KR (2)	KR20230130174A (da)
CN (1)	CN110267990B (da)
AU (1)	AU2017321625A1 (da)
CA (1)	CA3035343A1 (da)
DK (1)	DK3507306T3 (da)
HR (1)	HRP20251424T1 (da)
IL (1)	IL265046B2 (da)
MX (1)	MX2023006786A (da)
SG (1)	SG11201901712YA (da)
ZA (1)	ZA201901752B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2915378T3 (es) *	2013-09-13	2022-06-22	Hoffmann La Roche	Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102170077B1 (ko) *	2018-05-21	2020-10-27	인하대학교 산학협력단	Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
EP3873940A4 (en) *	2018-10-31	2022-11-30	BioAtla, Inc.	ANTI-CTLA4 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNE CONJUGATES AND USES THEREOF
CN115698075A (zh) *	2020-04-14	2023-02-03	葛兰素史密斯克莱知识产权发展有限公司	涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
WO2021209356A1 (en) *	2020-04-14	2021-10-21	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
US20220073586A1 (en) *	2020-09-08	2022-03-10	Eutilex Co., Ltd.	Pd-1 polypeptide variants
CN114195900B (zh) *	2020-09-17	2024-02-23	普米斯生物技术(珠海)有限公司	一种抗4-1bb/pd-l1双特异性抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8546543B2 (en) *	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8217149B2 (en) *	2008-12-09	2012-07-10	Genentech, Inc.	Anti-PD-L1 antibodies, compositions and articles of manufacture
EP2638072A4 (en) *	2010-11-12	2014-05-07	Univ Rockefeller	FUSION PROTEINS FOR HIV THERAPY
UY34887A (es) *	2012-07-02	2013-12-31	Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware	Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN105051069B (zh) *	2013-01-14	2019-12-10	Xencor股份有限公司	新型异二聚体蛋白
US10544187B2 (en) *	2013-03-15	2020-01-28	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
WO2014145806A2 (en) *	2013-03-15	2014-09-18	Xencor, Inc.	Heterodimeric proteins
BR112016001611B1 (pt) *	2013-07-25	2024-01-09	Cytomx Therapeutics, Inc	Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
DK3089994T3 (da)	2013-12-30	2022-07-04	Epimab Biotherapeutics Inc	Fabs-in-tandem-immunglobulin og anvendelser deraf
CA2964367C (en) *	2014-10-14	2024-01-30	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
LT3221346T (lt) *	2014-11-21	2020-11-10	Bristol-Myers Squibb Company	Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
AU2015353416C1 (en) *	2014-11-26	2022-01-27	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CD38
CN117843799A (zh) *	2015-01-08	2024-04-09	生物技术公司	激动性tnf受体结合剂
AU2016206707A1 (en) *	2015-01-14	2017-08-10	Compass Therapeutics Llc	Multispecific immunomodulatory antigen-binding constructs
MA41414A (fr) *	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos

2017
- 2017-08-30 SG SG11201901712YA patent/SG11201901712YA/en unknown
- 2017-08-30 JP JP2019511464A patent/JP7080219B2/ja active Active
- 2017-08-30 DK DK17765002.5T patent/DK3507306T3/da active
- 2017-08-30 KR KR1020237029969A patent/KR20230130174A/ko not_active Ceased
- 2017-08-30 KR KR1020197009280A patent/KR102575681B1/ko active Active
- 2017-08-30 CN CN201780060900.7A patent/CN110267990B/zh active Active
- 2017-08-30 AU AU2017321625A patent/AU2017321625A1/en not_active Abandoned
- 2017-08-30 IL IL265046A patent/IL265046B2/en unknown
- 2017-08-30 HR HRP20251424TT patent/HRP20251424T1/hr unknown
- 2017-08-30 CA CA3035343A patent/CA3035343A1/en active Pending
- 2017-08-30 EP EP17765002.5A patent/EP3507306B1/en active Active
2019
- 2019-02-27 MX MX2023006786A patent/MX2023006786A/es unknown
- 2019-03-20 ZA ZA2019/01752A patent/ZA201901752B/en unknown
2022
- 2022-05-24 JP JP2022084854A patent/JP2022111148A/ja active Pending

Also Published As

Publication number	Publication date
JP2019529368A (ja)	2019-10-17
SG11201901712YA (en)	2019-03-28
ZA201901752B (en)	2020-09-30
IL265046B1 (en)	2024-12-01
EP3507306A1 (en)	2019-07-10
MX2023006786A (es)	2023-06-20
RU2019109147A3 (da)	2021-01-22
CN110267990B (zh)	2023-11-07
AU2017321625A1 (en)	2019-04-04
KR20230130174A (ko)	2023-09-11
EP3507306B1 (en)	2025-10-01
CN110267990A (zh)	2019-09-20
HRP20251424T1 (hr)	2025-12-19
CA3035343A1 (en)	2018-03-08
JP7080219B2 (ja)	2022-06-03
IL265046B2 (en)	2025-04-01
KR20190044106A (ko)	2019-04-29
IL265046A (en)	2019-04-30
KR102575681B1 (ko)	2023-09-08
RU2019109147A (ru)	2020-10-05
JP2022111148A (ja)	2022-07-29

Publication	Publication Date	Title
ZA202203250B (en)	2022-05-25	Cd3 binding antibodies
IL269531A (en)	2019-11-28	Improved antigen binding receptors
DK3223845T3 (da)	2021-08-16	Heterodimere antistoffer, der binder cd3 og cd20
DK3328889T3 (da)	2021-08-23	Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
DK3328892T3 (da)	2021-06-14	Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
IL263840A (en)	2019-01-31	cd3 binding antibodies
HRP20181802T1 (hr)	2018-12-28	Protutijela koja vežu humani cd3
DK3356411T3 (da)	2021-09-06	Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
DK3328893T3 (da)	2023-12-11	Bispecifikke antistofkonstruktioner, der binder mesothelin og cd3
DK3328888T5 (da)	2024-10-07	ANTI-PSMA-antistoffer, bispecifikke antigenbindingsmolekyler, der binder PSMA AND og CD3, samt anvendelser deraf
DK3592384T3 (da)	2025-09-15	Antistoffer, der specifikt binder til human il-1r7
DK3370768T3 (da)	2022-03-21	Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3097122T3 (da)	2020-08-10	Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
DK3558369T3 (da)	2025-05-19	Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
DK3583120T3 (da)	2022-12-19	Modificerede transferrinreceptorbindende polypeptider
DK3487882T3 (da)	2025-09-22	Anti-gprc5d-antistoffer, bispecifikke antigenbindende molekyler, der binder gprc5d og cd3, samt anvendelser deraf
DK3507306T3 (da)	2025-10-20	Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer
DK3122781T3 (da)	2020-03-16	Bispecifikke antistoffer, der binder til cd38 og cd3
DK3710484T3 (da)	2023-11-27	Ctla-4-bindende antistoffer og anvendelser deraf
LT3247725T (lt)	2020-10-12	Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
DK3353212T3 (da)	2021-12-20	Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3362477T3 (da)	2022-03-07	Antigenbindingsproteiner, der aktiverer leptinreceptoren
DK3665198T3 (da)	2025-04-28	Antistoffer, der binder egfr og cmet
DK3182999T3 (da)	2021-03-15	Anti-lag3-antistoffer og antigenbindingsfragmenter
DK3110849T3 (da)	2020-11-23	Antistof, der binder erbb-2 og erbb-3